Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics
Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery. With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 pandemic, investigations into applying LNPs to deliver inhaled therapeutics directly to the lungs are underway. The...
| Published in: | Biomedicines |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/9/2179 |